Liposomal irinotecan in the treatment of refractory pancreatic cancer

Harold Bien, Gerardo Mackenzie, Minsig Choi

Research output: Contribution to journalReview article

Abstract

Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were available for second line therapy in metastatic pancreatic cancer. Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have progressed after gemcitabine-based therapy in a large, international, randomized clinical trial (NAPOLI-1). We reviewed the background of systemic therapy for metastatic pancreatic cancer, examined putative mechanisms for the success of encapsulated drugs, and identified recent patent applications on the use of liposomal irinotecan in pancreatic cancer. The landmark NAPOLI-1 trial established a second-line option for those with metastatic pancreatic cancer refractory to gemcitabine chemotherapy, but effective therapies with long duration of response are still lacking. Alternative techniques targeting key driver genes in pancreatic cancer and novel methods of early detection and targeting drugs are currently being explored. How liposomal irinotecan can be integrated into chemotherapy regimens, including neoadjuvant or first line combinations, are currently being tested in clinical trials and covered by several new patent applications.

Original languageEnglish (US)
Pages (from-to)376-383
Number of pages8
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume11
Issue number4
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

irinotecan
Pancreatic Neoplasms
gemcitabine
Therapeutics
Drug Therapy
Leucovorin
Drug Delivery Systems
Fluorouracil
Randomized Controlled Trials

Keywords

  • Liposomal irinotecan
  • MM-398
  • Nal-IRI
  • NAPOLI-1
  • Pancreatic cancer
  • Refractory cancer

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Liposomal irinotecan in the treatment of refractory pancreatic cancer. / Bien, Harold; Mackenzie, Gerardo; Choi, Minsig.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, No. 4, 01.11.2016, p. 376-383.

Research output: Contribution to journalReview article

@article{46b478548b454ffe81df327f4178fd12,
title = "Liposomal irinotecan in the treatment of refractory pancreatic cancer",
abstract = "Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were available for second line therapy in metastatic pancreatic cancer. Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have progressed after gemcitabine-based therapy in a large, international, randomized clinical trial (NAPOLI-1). We reviewed the background of systemic therapy for metastatic pancreatic cancer, examined putative mechanisms for the success of encapsulated drugs, and identified recent patent applications on the use of liposomal irinotecan in pancreatic cancer. The landmark NAPOLI-1 trial established a second-line option for those with metastatic pancreatic cancer refractory to gemcitabine chemotherapy, but effective therapies with long duration of response are still lacking. Alternative techniques targeting key driver genes in pancreatic cancer and novel methods of early detection and targeting drugs are currently being explored. How liposomal irinotecan can be integrated into chemotherapy regimens, including neoadjuvant or first line combinations, are currently being tested in clinical trials and covered by several new patent applications.",
keywords = "Liposomal irinotecan, MM-398, Nal-IRI, NAPOLI-1, Pancreatic cancer, Refractory cancer",
author = "Harold Bien and Gerardo Mackenzie and Minsig Choi",
year = "2016",
month = "11",
day = "1",
doi = "10.2174/1574892811666160729094415",
language = "English (US)",
volume = "11",
pages = "376--383",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Liposomal irinotecan in the treatment of refractory pancreatic cancer

AU - Bien, Harold

AU - Mackenzie, Gerardo

AU - Choi, Minsig

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were available for second line therapy in metastatic pancreatic cancer. Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have progressed after gemcitabine-based therapy in a large, international, randomized clinical trial (NAPOLI-1). We reviewed the background of systemic therapy for metastatic pancreatic cancer, examined putative mechanisms for the success of encapsulated drugs, and identified recent patent applications on the use of liposomal irinotecan in pancreatic cancer. The landmark NAPOLI-1 trial established a second-line option for those with metastatic pancreatic cancer refractory to gemcitabine chemotherapy, but effective therapies with long duration of response are still lacking. Alternative techniques targeting key driver genes in pancreatic cancer and novel methods of early detection and targeting drugs are currently being explored. How liposomal irinotecan can be integrated into chemotherapy regimens, including neoadjuvant or first line combinations, are currently being tested in clinical trials and covered by several new patent applications.

AB - Effective therapies against metastatic pancreatic cancer remain limited, and despite treatment, many will ultimately progress. Previously, few options were available for second line therapy in metastatic pancreatic cancer. Liposomal encapsulated irinotecan, in combination with leucovorin-modulated fluorouracil, was found to significantly increase overall survival in patients who have progressed after gemcitabine-based therapy in a large, international, randomized clinical trial (NAPOLI-1). We reviewed the background of systemic therapy for metastatic pancreatic cancer, examined putative mechanisms for the success of encapsulated drugs, and identified recent patent applications on the use of liposomal irinotecan in pancreatic cancer. The landmark NAPOLI-1 trial established a second-line option for those with metastatic pancreatic cancer refractory to gemcitabine chemotherapy, but effective therapies with long duration of response are still lacking. Alternative techniques targeting key driver genes in pancreatic cancer and novel methods of early detection and targeting drugs are currently being explored. How liposomal irinotecan can be integrated into chemotherapy regimens, including neoadjuvant or first line combinations, are currently being tested in clinical trials and covered by several new patent applications.

KW - Liposomal irinotecan

KW - MM-398

KW - Nal-IRI

KW - NAPOLI-1

KW - Pancreatic cancer

KW - Refractory cancer

UR - http://www.scopus.com/inward/record.url?scp=85004074739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004074739&partnerID=8YFLogxK

U2 - 10.2174/1574892811666160729094415

DO - 10.2174/1574892811666160729094415

M3 - Review article

C2 - 27480831

AN - SCOPUS:85004074739

VL - 11

SP - 376

EP - 383

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 4

ER -